Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMA402 first-in-human phase I/II trial in PRAME-positive recurrent or refractory solid tumors
2022-503133-54-00Phase 2Authorised
- Sponsor
- Immatics
- Start
- Aug 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label trial of IMA402 in Nonhematologic neoplasms (2 arms), sponsored by Immatics. Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events and 3 more. Planned start Aug 2023; status: authorised.
02
Drugs
IMA402
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2022-503133-54-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503133-54-00.